Vertex Pharmaceuticals Incorporated (0QZU.L)
USD 454.25
(-3.03%)
USD 454.25
(-3.03%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 808.4 Million USD | 44.1% |
| 2022 | 561 Million USD | 0.77% |
| 2021 | 556.7 Million USD | -4.26% |
| 2020 | 581.47 Million USD | 0.71% |
| 2019 | 577.37 Million USD | 1.8% |
| 2018 | 567.16 Million USD | 0.58% |
| 2017 | 563.91 Million USD | -32.73% |
| 2016 | 838.24 Million USD | 2.15% |
| 2015 | 820.61 Million USD | -0.57% |
| 2014 | 825.29 Million USD | 87.17% |
| 2013 | 440.93 Million USD | -34.45% |
| 2012 | 672.63 Million USD | 68.16% |
| 2011 | 400 Million USD | -25.51% |
| 2010 | 536.99 Million USD | 249.07% |
| 2009 | 153.83 Million USD | -46.49% |
| 2008 | 287.5 Million USD | 1337.72% |
| 2007 | 19.99 Million USD | -83.84% |
| 2006 | 123.75 Million USD | -31.28% |
| 2005 | 180.09 Million USD | -46.24% |
| 2004 | 334.99 Million USD | -3.01% |
| 2003 | 345.38 Million USD | 5.26% |
| 2002 | 328.13 Million USD | 0.16% |
| 2001 | 327.6 Million USD | -6.32% |
| 2000 | 349.69 Million USD | 4825.21% |
| 1999 | 7.1 Million USD | -27.55% |
| 1998 | 9.8 Million USD | 16.67% |
| 1997 | 8.4 Million USD | -1.18% |
| 1996 | 8.5 Million USD | 21.43% |
| 1995 | 7 Million USD | 9.38% |
| 1994 | 6.4 Million USD | 6.67% |
| 1993 | 6 Million USD | 17.65% |
| 1992 | 5.1 Million USD | 54.55% |
| 1991 | 3.3 Million USD | 3.13% |
| 1990 | 3.2 Million USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 721.3 Million USD | -10.77% |
| 2024 Q2 | 933.4 Million USD | 29.41% |
| 2024 Q3 | 1.7 Billion USD | 82.44% |
| 2023 Q1 | 789.2 Million USD | 40.68% |
| 2023 Q3 | 744.7 Million USD | -2.98% |
| 2023 FY | 808.4 Million USD | 44.1% |
| 2023 Q2 | 767.6 Million USD | -2.74% |
| 2023 Q4 | 808.4 Million USD | 8.55% |
| 2022 FY | 561 Million USD | 0.77% |
| 2022 Q2 | 531.6 Million USD | -2.32% |
| 2022 Q3 | 482 Million USD | -9.33% |
| 2022 Q4 | 561 Million USD | 16.39% |
| 2022 Q1 | 544.2 Million USD | -2.25% |
| 2021 Q2 | 569.75 Million USD | -0.54% |
| 2021 FY | 556.7 Million USD | -4.26% |
| 2021 Q1 | 572.85 Million USD | -1.48% |
| 2021 Q3 | 558.93 Million USD | -1.9% |
| 2021 Q4 | 556.7 Million USD | -0.4% |
| 2020 Q4 | 581.47 Million USD | -1.07% |
| 2020 Q2 | 562.47 Million USD | -1.82% |
| 2020 Q3 | 587.77 Million USD | 4.5% |
| 2020 FY | 581.47 Million USD | 0.71% |
| 2020 Q1 | 572.91 Million USD | -0.77% |
| 2019 Q1 | 596.1 Million USD | 5.1% |
| 2019 FY | 577.37 Million USD | 1.8% |
| 2019 Q4 | 577.37 Million USD | -0.22% |
| 2019 Q3 | 578.62 Million USD | -1.69% |
| 2019 Q2 | 588.57 Million USD | -1.26% |
| 2018 Q1 | 567.49 Million USD | 0.64% |
| 2018 Q4 | 567.16 Million USD | 0.25% |
| 2018 Q2 | 570.12 Million USD | 0.46% |
| 2018 Q3 | 565.74 Million USD | -0.77% |
| 2018 FY | 567.16 Million USD | 0.58% |
| 2017 Q2 | 525.54 Million USD | 5.26% |
| 2017 Q4 | 563.91 Million USD | 2.99% |
| 2017 FY | 563.91 Million USD | -32.73% |
| 2017 Q1 | 499.28 Million USD | -40.44% |
| 2017 Q3 | 547.54 Million USD | 4.19% |
| 2016 FY | 838.24 Million USD | 2.15% |
| 2016 Q3 | 815.74 Million USD | -0.65% |
| 2016 Q4 | 838.24 Million USD | 2.76% |
| 2016 Q2 | 821.09 Million USD | -0.47% |
| 2016 Q1 | 824.94 Million USD | 0.53% |
| 2015 Q3 | 820.98 Million USD | -0.42% |
| 2015 Q1 | 833.9 Million USD | 1.04% |
| 2015 Q2 | 824.46 Million USD | -1.13% |
| 2015 FY | 820.61 Million USD | -0.57% |
| 2015 Q4 | 820.61 Million USD | -0.04% |
| 2014 Q1 | 473.36 Million USD | 7.35% |
| 2014 Q3 | 767.91 Million USD | 62.26% |
| 2014 FY | 825.29 Million USD | 87.17% |
| 2014 Q4 | 825.29 Million USD | 7.47% |
| 2014 Q2 | 473.26 Million USD | -0.02% |
| 2013 Q4 | 440.93 Million USD | 12.32% |
| 2013 Q3 | 392.56 Million USD | 9.32% |
| 2013 Q2 | 359.1 Million USD | -49.9% |
| 2013 Q1 | 716.82 Million USD | 6.57% |
| 2013 FY | 440.93 Million USD | -34.45% |
| 2012 Q3 | 400 Million USD | 0.0% |
| 2012 FY | 672.63 Million USD | 68.16% |
| 2012 Q1 | 400 Million USD | 0.0% |
| 2012 Q4 | 672.63 Million USD | 68.16% |
| 2012 Q2 | 400 Million USD | 0.0% |
| 2011 Q2 | 400 Million USD | 0.0% |
| 2011 FY | 400 Million USD | -25.51% |
| 2011 Q4 | 400 Million USD | 0.0% |
| 2011 Q3 | 400 Million USD | 0.0% |
| 2011 Q1 | 400 Million USD | -25.51% |
| 2010 Q1 | 125.31 Million USD | -18.54% |
| 2010 FY | 536.99 Million USD | 249.07% |
| 2010 Q4 | 536.99 Million USD | 34.25% |
| 2010 Q3 | 400 Million USD | 362.93% |
| 2010 Q2 | 86.4 Million USD | -31.05% |
| 2009 FY | 153.83 Million USD | -46.49% |
| 2009 Q1 | 287.5 Million USD | 0.0% |
| 2009 Q2 | 144 Million USD | -49.91% |
| 2009 Q3 | 144 Million USD | 0.0% |
| 2009 Q4 | 153.83 Million USD | 6.83% |
| 2008 Q1 | 287.5 Million USD | 1337.72% |
| 2008 Q2 | 287.5 Million USD | 0.0% |
| 2008 Q3 | 287.5 Million USD | 0.0% |
| 2008 Q4 | 287.5 Million USD | 0.0% |
| 2008 FY | 287.5 Million USD | 1337.72% |
| 2007 Q1 | 65.22 Million USD | -47.29% |
| 2007 Q2 | 62.09 Million USD | -4.79% |
| 2007 FY | 19.99 Million USD | -83.84% |
| 2007 Q4 | 19.99 Million USD | 0.0% |
| 2007 Q3 | 19.99 Million USD | -67.8% |
| 2006 Q1 | 180.09 Million USD | 0.0% |
| 2006 Q4 | 123.75 Million USD | 21.63% |
| 2006 Q2 | 180.09 Million USD | -0.0% |
| 2006 Q3 | 101.75 Million USD | -43.5% |
| 2006 FY | 123.75 Million USD | -31.28% |
| 2005 Q3 | 294.54 Million USD | -12.07% |
| 2005 Q4 | 180.09 Million USD | -38.86% |
| 2005 Q1 | 334.99 Million USD | 0.0% |
| 2005 FY | 180.09 Million USD | -46.24% |
| 2005 Q2 | 334.99 Million USD | 0.0% |
| 2004 Q4 | 334.99 Million USD | 4.79% |
| 2004 Q1 | 315.03 Million USD | -8.79% |
| 2004 Q2 | 322.61 Million USD | 2.41% |
| 2004 Q3 | 319.68 Million USD | -0.91% |
| 2004 FY | 334.99 Million USD | -3.01% |
| 2003 Q1 | 329.89 Million USD | 0.54% |
| 2003 FY | 345.38 Million USD | 5.26% |
| 2003 Q3 | 345.33 Million USD | 1.34% |
| 2003 Q4 | 345.38 Million USD | 0.02% |
| 2003 Q2 | 340.77 Million USD | 3.3% |
| 2002 Q3 | 324.28 Million USD | -0.3% |
| 2002 Q4 | 328.13 Million USD | 1.19% |
| 2002 Q2 | 325.24 Million USD | -0.31% |
| 2002 Q1 | 326.25 Million USD | -0.41% |
| 2002 FY | 328.13 Million USD | 0.16% |
| 2001 Q2 | 348.64 Million USD | -0.14% |
| 2001 Q3 | 358.74 Million USD | 2.9% |
| 2001 FY | 327.6 Million USD | -6.32% |
| 2001 Q4 | 327.6 Million USD | -8.68% |
| 2001 Q1 | 349.15 Million USD | -0.15% |
| 2000 Q4 | 349.69 Million USD | -31.69% |
| 2000 Q3 | 511.92 Million USD | 183.11% |
| 2000 Q2 | 180.82 Million USD | -0.33% |
| 2000 Q1 | 181.42 Million USD | 2455.31% |
| 2000 FY | 349.69 Million USD | 4825.21% |
| 1999 Q1 | 9.1 Million USD | -7.14% |
| 1999 Q2 | 8.4 Million USD | -7.69% |
| 1999 Q3 | 7.8 Million USD | -7.14% |
| 1999 Q4 | 7.1 Million USD | -8.97% |
| 1999 FY | 7.1 Million USD | -27.55% |
| 1998 Q2 | 9.6 Million USD | 10.34% |
| 1998 Q1 | 8.7 Million USD | 3.57% |
| 1998 Q3 | 10.4 Million USD | 8.33% |
| 1998 Q4 | 9.8 Million USD | -5.77% |
| 1998 FY | 9.8 Million USD | 16.67% |
| 1997 Q4 | 8.4 Million USD | 2.44% |
| 1997 Q2 | 8.2 Million USD | 1.23% |
| 1997 Q1 | 8.1 Million USD | -4.71% |
| 1997 FY | 8.4 Million USD | -1.18% |
| 1997 Q3 | 8.2 Million USD | 0.0% |
| 1996 Q1 | 6.5 Million USD | -7.14% |
| 1996 FY | 8.5 Million USD | 21.43% |
| 1996 Q3 | 6.9 Million USD | 0.0% |
| 1996 Q4 | 8.5 Million USD | 23.19% |
| 1996 Q2 | 6.9 Million USD | 6.15% |
| 1995 Q2 | 6.9 Million USD | 4.55% |
| 1995 Q3 | 6.8 Million USD | -1.45% |
| 1995 Q4 | 7 Million USD | 2.94% |
| 1995 FY | 7 Million USD | 9.38% |
| 1995 Q1 | 6.6 Million USD | 3.13% |
| 1994 FY | 6.4 Million USD | 6.67% |
| 1994 Q2 | 6 Million USD | 9.09% |
| 1994 Q3 | 6.3 Million USD | 5.0% |
| 1994 Q1 | 5.5 Million USD | -8.33% |
| 1994 Q4 | 6.4 Million USD | 1.59% |
| 1993 Q4 | 6 Million USD | 1.69% |
| 1993 Q1 | 5.3 Million USD | 3.92% |
| 1993 Q2 | 5.9 Million USD | 11.32% |
| 1993 FY | 6 Million USD | 17.65% |
| 1993 Q3 | 5.9 Million USD | 0.0% |
| 1992 Q2 | 4.4 Million USD | 22.22% |
| 1992 FY | 5.1 Million USD | 54.55% |
| 1992 Q1 | 3.6 Million USD | 9.09% |
| 1992 Q3 | 5 Million USD | 13.64% |
| 1992 Q4 | 5.1 Million USD | 2.0% |
| 1991 FY | 3.3 Million USD | 3.13% |
| 1991 Q2 | 3.5 Million USD | 0.0% |
| 1991 Q3 | 3.5 Million USD | 0.0% |
| 1991 Q4 | 3.3 Million USD | -5.71% |
| 1990 FY | 3.2 Million USD | 0.0% |
| 1990 Q4 | 3.2 Million USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Dynavax Technologies Corporation | 256.91 Million USD | -214.658% |
| Walgreens Boots Alliance, Inc. | 9.55 Billion USD | 91.539% |
| Supernus Pharmaceuticals, Inc. | 41.52 Million USD | -1846.685% |
| Perrigo Company plc | 4.07 Billion USD | 80.154% |
| Illumina, Inc. | 2.26 Billion USD | 64.262% |
| Thermo Fisher Scientific Inc. | 34.91 Billion USD | 97.685% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -80740.0% |
| IQVIA Holdings Inc. | 14.23 Billion USD | 94.319% |
| Heron Therapeutics, Inc. | 173.75 Million USD | -365.258% |
| Unity Biotechnology, Inc. | 26.99 Million USD | -2895.183% |
| Waters Corporation | 2.35 Billion USD | 65.681% |
| Biogen Inc. | 7.33 Billion USD | 88.984% |
| Sangamo Therapeutics, Inc. | 38.1 Million USD | -2021.562% |
| Evolus, Inc. | 126.54 Million USD | -538.819% |
| Adicet Bio, Inc. | 17.7 Million USD | -4466.458% |
| Esperion Therapeutics, Inc. | 540.94 Million USD | -49.442% |
| FibroGen, Inc. | 170.45 Million USD | -374.26% |
| Agilent Technologies, Inc. | 2.73 Billion USD | 70.442% |
| Homology Medicines, Inc. | 44.05 Million USD | -1735.021% |
| Geron Corporation | 85.89 Million USD | -841.105% |
| Alnylam Pharmaceuticals, Inc. | 2.39 Billion USD | 66.289% |
| Editas Medicine, Inc. | 36.53 Million USD | -2112.612% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 70.091% |
| Amicus Therapeutics, Inc. | 445.05 Million USD | -81.639% |
| Cara Therapeutics, Inc. | 43.16 Million USD | -1772.727% |
| bluebird bio, Inc. | 330.32 Million USD | -144.728% |
| Myriad Genetics, Inc. | 145 Million USD | -457.517% |
| Corbus Pharmaceuticals Holdings, Inc. | 20.88 Million USD | -3770.863% |
| BioMarin Pharmaceutical Inc. | 1.13 Billion USD | 28.705% |
| Viking Therapeutics, Inc. | 1.26 Million USD | -64058.73% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | 115.34 Million USD | -600.848% |
| Zoetis Inc. | 6.8 Billion USD | 88.117% |
| Abeona Therapeutics Inc. | 4.4 Million USD | -18264.38% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | 62.708% |
| Atara Biotherapeutics, Inc. | 57.87 Million USD | -1296.876% |
| Nektar Therapeutics | 230.4 Million USD | -250.867% |
| Axsome Therapeutics, Inc. | 186.37 Million USD | -333.756% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | -26197.983% |
| Kala Pharmaceuticals, Inc. | 36.32 Million USD | -2125.587% |
| Ionis Pharmaceuticals, Inc. | 1.45 Billion USD | 44.384% |
| Verastem, Inc. | 41.55 Million USD | -1845.28% |
| OPKO Health, Inc. | 326.56 Million USD | -147.547% |
| Exelixis, Inc. | 189.94 Million USD | -325.599% |
| Imunon, Inc. | 1.13 Million USD | -70856.286% |
| Sarepta Therapeutics, Inc. | 1.39 Billion USD | 42.125% |
| uniQure N.V. | 138.4 Million USD | -484.066% |
| Neurocrine Biosciences, Inc. | 428.4 Million USD | -88.702% |
| Corcept Therapeutics Incorporated | 151 Thousand USD | -535264.238% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | 46.08% |
| Blueprint Medicines Corporation | 774.12 Million USD | -4.428% |
| Insmed Incorporated | 1.2 Billion USD | 32.857% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | -1318.544% |
| TG Therapeutics, Inc. | 110.79 Million USD | -629.636% |
| Incyte Corporation | 38.28 Million USD | -2011.422% |
| Emergent BioSolutions Inc. | 877.5 Million USD | 7.875% |